Peptide Therapy at Tactus Health
Two clinician-prescribed peptides with established safety profiles and meaningful clinical evidence: Sermorelin for growth hormone support, PT-141 for sexual wellness. Both legal. Both evidence-based. Both require a real clinical evaluation before our providers write a single prescription.
We do not prescribe BPC-157, CJC-1295, Ipamorelin, or any other FDA Category 2 compound. Clinics that do are operating outside FDA guidelines.
This Is Not a Supplement. It Is a Prescription.
The wellness market has turned peptides into a buzzword. Every online pharmacy offers BPC-157. Every gym has someone injecting CJC-1295. Most of it is unmonitored, and much of it is sourced from laboratories that operate outside FDA oversight.
At Tactus Health, peptide therapy means two legally compoundable, clinically supported molecules, prescribed after our providers review your labs and health history, and dispensed by a licensed 503A pharmacy that tests every batch for sterility and potency. If that sounds like more friction than clicking a button online, it is. That friction is the point.
What Is Peptide Therapy?
Peptides are short chains of amino acids that act as biological signaling molecules. Unlike hormone replacement, which substitutes what your body has stopped producing, peptides work by stimulating your own biological processes. Sermorelin tells your pituitary to release more growth hormone through the same feedback loop your body already uses. PT-141 activates melanocortin receptors in your central nervous system to influence desire. The mechanism is with your biology, not instead of it.
The clinical use of peptides is not new. Sermorelin has been prescribed as both a diagnostic and therapeutic agent since the 1990s. PT-141 (bremelanotide) holds FDA approval as Vyleesi for premenopausal women with hypoactive sexual desire disorder. What has changed is access: both are now available via telehealth with lab review and a prescription from a qualified clinician.
What has not changed is the clinical requirement: a real consultation, a lab review, and a prescription from a licensed provider. Peptides are not supplements. They require clinical oversight and monitoring to confirm your biology is responding.
Sermorelin requires an IGF-1 (Insulin-like Growth Factor 1) blood test to establish your baseline before prescribing, and a 90-day follow-up to confirm your pituitary gland’s response. We do not guess. We measure.
How Peptide Therapy at Tactus Health Works
Lab review first. Prescription second. Medication ships directly to you.
15 to 30 min with Dr. Ashar. Full health history and medication review.
Walk-in at any Quest or Labcorp. Results in 48 to 72 hours.
Your prescribing clinician reviews your case personally and writes your prescription.
Temperature-controlled, discreet packaging with video tutorial included.
Your Medical Director reviews IGF-1 results and adjusts the protocol if needed.
The Clinical Evaluation: What Happens Before a Prescription Is Written
Before our providers prescribe Sermorelin, they review your IGF-1 level, hormone panel, current medications, and any conditions that would change their approach or disqualify you as a candidate. If your IGF-1 is already optimal, Sermorelin may not be indicated. If it is low, we have a clinical target to work toward.
Schedule your clinical evaluation →Peptides vs. Hormone Replacement: The Biological Distinction
Hormone Replacement (TRT/HRT): Introduces a synthetic or bioidentical hormone to replace what your body is no longer producing. The body detects elevated hormone levels and, through a negative feedback loop, often reduces or halts its own natural production over time. You are replacing. Your feedback loop adjusts accordingly.
Peptide Therapy (Sermorelin): Acts as a secretagogue. It signals your pituitary gland to produce and release its own growth hormone through the same feedback mechanisms your body already uses. Because the pathway stays intact, excess production is naturally self-limited. This is a categorically different risk profile compared to synthetic HGH.
PT-141 operates through a third pathway: CNS melanocortin receptors. It does not replace a hormone or stimulate a gland. It activates a neurological signal that influences desire, with no reproductive hormone involved.
Synthetic HGH bypasses your pituitary entirely, flooding the system with externally sourced growth hormone. Your feedback loop detects excess and suppresses endogenous production. Long-term, this can impair your pituitary’s ability to self-regulate. Sermorelin stimulates the pituitary through the normal pathway, preserving the body’s own production and self-limiting mechanisms.
Sermorelin is a GHRH analogue. It works upstream of the hormone, not instead of it.
We prefer peptides for patients whose biological pathways are still intact but need a clinical signal to return to more youthful function levels. The moment the pathway is compromised or the benefit is outweighed by another approach, we discuss alternatives. The IGF-1 data at 90 days tells us whether the pathway responded. We do not continue protocols that are not producing measurable results.
Two Peptides. Both Clinically Supported. Both Legal.
Click through for the full guide on each: mechanism, protocol, dosing, timeline, and what to expect.
Sermorelin stimulates your pituitary gland to produce more of your own growth hormone naturally, through your body’s existing feedback loop, not synthetic HGH replacement. Prescribed after a full hormone panel and IGF-1 baseline.
- Improved body composition: increased lean mass and reduced visceral fat
- Deeper, more restorative sleep, often reported within 2 to 4 weeks
- Faster recovery from exercise and physical stress
- 90-day IGF-1 follow-up confirms pituitary response
PT-141 (bremelanotide) is the active ingredient in Vyleesi, FDA-approved for hypoactive sexual desire disorder in premenopausal women. Works through the central nervous system via melanocortin receptors, not the vascular system. Distinct from PDE-5 inhibitors. Available for both men and women.
- Increased libido and sexual desire, acts centrally not vascularly
- Improved arousal and sexual response in both men and women
- Addresses desire where PDE-5 inhibitors do not fully reach
- As-needed dosing, no daily injection schedule required
Is Peptide Therapy Right for You?
Peptides are not a universal solution. But for specific presentations, they are among the most targeted and evidence-supported tools available.
Growth hormone declines progressively after 30. Sermorelin is often a strong fit for men who feel the gap between how they used to recover and how they recover now, particularly combined with TRT.
PT-141 is FDA-approved for premenopausal women with HSDD and is frequently prescribed alongside HRT for women where desire has not returned with hormonal optimization alone.
Sermorelin is frequently prescribed to weight loss patients to protect lean muscle mass and maintain energy during active fat loss. As body fat decreases, Sermorelin counters muscle loss that can accompany aggressive caloric restriction.
PT-141 targets the CNS desire pathway, not the vascular system. Patients who have physical response but not desire often respond well. Different mechanism, different patient profile.
Sermorelin’s most commonly reported early effect is sleep quality improvement. For patients where poor sleep is compounding energy, mood, and metabolic issues, it is often the most direct lever.
Patients with active malignancy, certain cardiovascular conditions, or those already on synthetic HGH. Our providers review all contraindications at consultation. No protocol is started without the clinical evaluation.
Why We Only Offer Two Peptides
The peptide market is flooded with compounds marketed as safe and effective. BPC-157, CJC-1295, Ipamorelin, TB-500, and others may have real potential. Most lack the human clinical trial data needed to make confident claims about safety and efficacy in real patients over time.
BPC-157 remains on the FDA’s Category 2 bulk drug substances list, prohibiting compounding by licensed 503A pharmacies. CJC-1295 and Ipamorelin were removed from Category 2 in 2024 after nominators withdrew their applications, but they are not approved and remain under ongoing FDA review. None are legally available for routine compounding today. Clinics prescribing them are operating outside current FDA guidance.
At Tactus Health, we prescribe what is legally compoundable, clinically supported, and backed by evidence we would want as patients. That is Sermorelin and PT-141. If the regulatory landscape changes and additional peptides gain appropriate compounding status, we will add them.
All peptide prescriptions go to licensed 503A pharmacies complying with USP standards. Prepared in a certified clean room, tested for sterility and potency, shipped in temperature-controlled packaging directly to your door.
BPC-157 remains on the FDA’s Category 2 list as of this writing, prohibiting compounding for human use. CJC-1295 and Ipamorelin were removed from Category 2 in 2024 after nominators withdrew applications, but they are still unapproved and pending further FDA review. None are available for routine 503A compounding today. We follow the FDA’s current guidance and update our protocols whenever regulatory status changes.
Sermorelin vs. PT-141: Which Is Right for You?
Two different mechanisms. Two different goals. Our providers determine the right fit at consultation.
What to Expect
Our providers review your health history, current medications, and goals. Your provider determines whether peptide therapy is indicated, which peptide is the right fit, and what baseline labs are needed. No treatment the same day unless you choose it. No pressure.
If Sermorelin is indicated, our providers send an IGF-1 and hormone panel order electronically. You walk into any Quest or Labcorp near you, no appointment needed at most sites. Results in 48 to 72 hours. For PT-141, labs may not be required depending on your history.
Our providers review your results personally and write your prescription. It goes to a licensed 503A compounding pharmacy. Your medication arrives in 5 to 7 days in temperature-controlled, discreet packaging. A complete video tutorial on self-injection is included.
At 90 days, our providers order a repeat IGF-1 blood test to confirm your pituitary gland has responded. If your IGF-1 has not moved into the optimal range, our medical team adjusts your titration or evaluates whether a different approach is warranted. We do not set and forget.
Every Prescription Written and Monitored by Dr. Ashar
Dr. Ashar N.
Dr. Ashar holds a Doctor of Nursing Practice and two national board certifications, one in family practice and one in psychiatric mental health.
She founded Tactus Health to close the gap she watched her own family fall through: symptoms that were real, labs that came back normal, and no one willing to connect the two.
She is responsible for the protocols our medical team follows, and for the training of the clinicians who deliver them. Holding both certifications is why those protocols treat hormones, mood, sleep and metabolism as one system rather than five separate appointments.
The 90-Day IGF-1 Check: We Do Not Set and Forget
At 90 days, our providers order a repeat IGF-1 to confirm your pituitary is responding. If IGF-1 has not moved into the optimal range, our medical team evaluates metabolic health, medication interactions, and whether titration should change. For patients on both Sermorelin and GLP-1 therapy, we specifically monitor lean muscle preservation alongside fat loss.
Start with a free clinical evaluation →Peptide Therapy Available by Telehealth
Both Sermorelin and PT-141 can be prescribed via telehealth and shipped to your door. Availability varies by state, and our team confirms your eligibility during your free consultation.
Explore peptide therapy via telehealth →
Maintaining Your Results
Peptide therapy is a monitored, ongoing protocol, not a one-time purchase. Here is how to get the most from your program.
Sermorelin works through repeated nightly signaling. Skipping doses disrupts the cycle. Most patients notice clear results by weeks 8 to 12 on a consistent protocol.
The IGF-1 recheck at 90 days tells us whether your pituitary responded and whether titration needs adjustment. Without it, there is no clinical basis for continuing the protocol.
Sermorelin and TRT address separate hormone axes, producing better combined outcomes than either alone. On GLP-1? Sermorelin preserves lean muscle during fat loss. See all telehealth services →
Peptide Therapy FAQ
For the two peptides we prescribe, yes, when properly evaluated and dosed. Sermorelin has a long clinical record as both a diagnostic and therapeutic agent. PT-141 (bremelanotide) is FDA-approved as Vyleesi. Both are compounded by licensed 503A pharmacies to USP standards. Our providers review your full health history before prescribing either.
These compounds are on the FDA’s Category 2 bulk drug substances list, which prohibits their compounding by 503A and 503B pharmacies for human use. Prescribing them would place us outside FDA guidelines. Whatever their potential, we will not prescribe compounds that are not legally compoundable. If their status changes, we will revisit.
Often yes. Sermorelin is commonly combined with TRT to support the full hormonal optimization picture. PT-141 is frequently prescribed alongside HRT or GLP-1 programs where sexual wellness is a focus. Dr. Ashar evaluates all current medications before prescribing any peptide to confirm there are no contraindications.
Sleep improvements are typically the first thing patients notice, usually within 2 to 4 weeks. Body composition changes, including reduced fat and increased lean mass, generally take 8 to 12 weeks at a consistent dose to become visible. Patients are evaluated at 90 days with an IGF-1 blood test to assess growth hormone response and titration needs.
No. PT-141’s FDA approval covers premenopausal women with HSDD, but it is prescribed off-label for men as well. It works by activating melanocortin receptors in the central nervous system, which influences sexual desire regardless of sex. Men who have not had full resolution with PDE-5 inhibitors are often strong candidates. Dr. Ashar evaluates candidacy at consultation.
For Sermorelin, yes. A baseline hormone panel including IGF-1 (Insulin-like Growth Factor 1) is required to confirm candidacy and establish the monitoring baseline. For PT-141, labs may not be required depending on your health history. If you have had recent bloodwork with your primary doctor in the last 12 months, our providers can often review those records to expedite your protocol.
Enhance Your Results
TRT and Sermorelin address separate hormone axes. Combined, they cover the full optimization picture neither addresses alone.
Sermorelin is frequently added to active GLP-1 programs to protect lean muscle mass during aggressive fat loss.
PT-141 is frequently added for women on HRT where desire has not returned with hormonal optimization alone.
Start Your Peptide Consultation: Free, No Commitment
Our providers review your health history and goals. IGF-1 lab review before prescribing Sermorelin. Shipped to your door. Only FDA-compliant peptides prescribed.Prescription required · Results vary